Roxane Receives First Generic Approval For Abbott’s Biaxin
This article was originally published in The Pink Sheet Daily
Executive Summary
ANDA for 250 mg and 500 mg tablets receives full approval from FDA. Abbott says compound patent runs until 2005.
You may also be interested in...
Aventis Launching Ketek With 1,800-Person Primary Care Sales Force
The sales force will begin detailing Ketek Aug. 2. The company has blockbuster expectations for the antibiotic, particularly in light of the upcoming patent expiration for Pfizer’s Zithromax.
Aventis Launching Ketek With 1,800-Person Primary Care Sales Force
The sales force will begin detailing Ketek Aug. 2. The company has blockbuster expectations for the antibiotic, particularly in light of the upcoming patent expiration for Pfizer’s Zithromax.
Andrx Receives First Generic Approval For Abbott's Biaxin XL
The generic firm does not plan to market clarithromycin extended-release 500 mg tablets until expiration of Abbott's compound patent in May 2005. Abbott says the XL formulation is patented through 2017.